Compare Lupin with Sanofi India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs SANOFI INDIA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN SANOFI INDIA LUPIN/
SANOFI INDIA
 
P/E (TTM) x 41.1 39.5 103.9% View Chart
P/BV x 3.8 8.0 46.9% View Chart
Dividend Yield % 0.6 1.1 53.0%  

Financials

 LUPIN   SANOFI INDIA
EQUITY SHARE DATA
    LUPIN
Mar-20
SANOFI INDIA
Dec-18
LUPIN/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs8826,840 12.9%   
Low Rs5054,630 10.9%   
Sales per share (Unadj.) Rs339.41,203.1 28.2%  
Earnings per share (Unadj.) Rs-5.9165.3 -3.6%  
Cash flow per share (Unadj.) Rs15.5209.9 7.4%  
Dividends per share (Unadj.) Rs6.0084.00 7.1%  
Dividend yield (eoy) %0.91.5 59.1%  
Book value per share (Unadj.) Rs276.7963.6 28.7%  
Shares outstanding (eoy) m453.0023.03 1,967.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.04.8 42.9%   
Avg P/E ratio x-116.634.7 -336.1%  
P/CF ratio (eoy) x44.827.3 164.1%  
Price / Book Value ratio x2.56.0 42.1%  
Dividend payout %-100.950.8 -198.5%   
Avg Mkt Cap Rs m314,201132,078 237.9%   
No. of employees `00018.33.3 554.4%   
Total wages/salary Rs m29,8684,068 734.2%   
Avg. sales/employee Rs Th8,400.68,393.8 100.1%   
Avg. wages/employee Rs Th1,632.01,232.4 132.4%   
Avg. net profit/employee Rs Th-147.21,153.0 -12.8%   
INCOME DATA
Net Sales Rs m153,74827,708 554.9%  
Other income Rs m4,838897 539.3%   
Total revenues Rs m158,58528,605 554.4%   
Gross profit Rs m24,8496,235 398.5%  
Depreciation Rs m9,7021,027 944.7%   
Interest Rs m3,6307 51,854.3%   
Profit before tax Rs m16,3556,098 268.2%   
Minority Interest Rs m40-   
Prior Period Items Rs m390-   
Extraordinary Inc (Exp) Rs m-7,5210-   
Tax Rs m11,5712,292 504.8%   
Profit after tax Rs m-2,6943,806 -70.8%  
Gross profit margin %16.222.5 71.8%  
Effective tax rate %70.837.6 188.2%   
Net profit margin %-1.813.7 -12.8%  
BALANCE SHEET DATA
Current assets Rs m154,13215,922 968.0%   
Current liabilities Rs m92,2526,235 1,479.6%   
Net working cap to sales %40.235.0 115.1%  
Current ratio x1.72.6 65.4%  
Inventory Days Days8264 129.0%  
Debtors Days Days12921 619.6%  
Net fixed assets Rs m89,0827,539 1,181.6%   
Share capital Rs m906230 393.9%   
"Free" reserves Rs m124,46121,962 566.7%   
Net worth Rs m125,36722,192 564.9%   
Long term debt Rs m17,9330-   
Total assets Rs m249,83929,839 837.3%  
Interest coverage x5.5872.1 0.6%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.9 66.3%   
Return on assets %0.412.8 2.9%  
Return on equity %-2.117.2 -12.5%  
Return on capital %8.727.5 31.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,4507,587 678.1%   
Fx outflow Rs m19,4707,145 272.5%   
Net fx Rs m31,980442 7,235.2%   
CASH FLOW
From Operations Rs m14,6883,739 392.8%  
From Investments Rs m11,070-731 -1,514.4%  
From Financial Activity Rs m-8,906-1,972 451.6%  
Net Cashflow Rs m16,8531,036 1,626.7%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 60.4 0.3%  
Indian inst/Mut Fund % 11.3 14.4 78.5%  
FIIs % 31.9 14.6 218.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 10.5 96.2%  
Shareholders   98,259 15,184 647.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   IPCA LABS  NOVARTIS  PANACEA BIOTECH  ORCHID PHARMA  GSK PHARMA  

Compare LUPIN With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tumbles 1,300 Points; IndusInd Bank, Axis Bank & ICICI Bank Fall Over 5%(09:30 am)

Asian stock markets are trading on a positive note today, helped by expectations monetary policy will remain accommodative.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY21); Net Profit Up 5.0% (Quarterly Result Update)

Oct 29, 2020 | Updated on Oct 29, 2020

For the quarter ended September 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 5.0% YoY). Sales on the other hand came in at Rs 7 bn (down 11.9% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (1QFY21); Net Profit Up 39.9% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, SANOFI INDIA has posted a net profit of Rs 1 bn (up 39.9% YoY). Sales on the other hand came in at Rs 7 bn (down 5.0% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Apr 19, 2021 12:05 PM

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS